FDA Approves Non-radioactive Tracer Able to Detect Lymph Nodes Affected by Breast Cancer

FDA Approves Non-radioactive Tracer Able to Detect Lymph Nodes Affected by Breast Cancer
The U.S. Food and Drug Administration (FDA) approved the non-radioactive tracer Magtrace for the pre-surgical detection of lymph nodes affected by breast cancer. Used in combination with Sentimag Magnetic Localization System, Magtrace allows surgeons to determine which lymph nodes might be affected by breast cancer cells. Doctors collect a biopsy from those nodes to look for signs of cancer before a patient undergoes breast cancer surgery. “We’ve been watching this technology become established in Europe over the past few years, and have been eagerly awaiting its availability in the US,” Michael Alvarado, professor of surgery at The University of California, San Francisco, said in a news release. “After 18 months of using the Sentimag platform with Magseed for lesion localization, we’re really excited to add the sentinel node biopsy capability with Magtrace,” Alvarado said. The typical treatment for breast cancer is to surgically remove the tumor and determine whether the cancer has spread. For that, clinicians must map the neighboring lymph nodes and determine which are connected to the tumor. This requires the use of  radioactive drugs and blue dyes. Magtrace<
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.